A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1
Recruiting
- Conditions
- Peripheral T-cell LymphomaCutaneous T-cell Lymphoma (CTCL)NHL (Non-Hodgkin Lymphoma)
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Target Recruit Count
- 24
- Registration Number
- NCT06914037
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Phase 2
Not yet recruiting
- Conditions
- Lung Cancer, Small CellLimited-stage Small Cell Lung Cancer (LS-SCLC)
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-25
- Target Recruit Count
- 30
- Registration Number
- NCT06914050
Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Target Recruit Count
- 31
- Registration Number
- NCT06890182
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-25
- Target Recruit Count
- 138
- Registration Number
- NCT06878625
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-10
- Target Recruit Count
- 20
- Registration Number
- NCT06867432
Second-line Immunotherapy for ES-SCLC
Not Applicable
Recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Target Recruit Count
- 30
- Registration Number
- NCT06853678
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
The Importance of Thymus Anatomy to the Radical Resection of Thyroid Cancer Surgery and the Protection of Parathyroid Function
Not Applicable
Not yet recruiting
- Conditions
- Thyroid CancerSurgery
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Target Recruit Count
- 5
- Registration Number
- NCT06851260
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
Not Applicable
Not yet recruiting
- Conditions
- Brain MetastasisSRS
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Target Recruit Count
- 34
- Registration Number
- NCT06852001
Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
Phase 2
Recruiting
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc)Gall Bladder Cancer
- Interventions
- Drug: chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab.
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Target Recruit Count
- 33
- Registration Number
- NCT06852287
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tia, China
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamour Cell Cancer
- Interventions
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-02-07
- Target Recruit Count
- 57
- Registration Number
- NCT06814158
- Locations
- 🇨🇳
Tianjin Medical University Cancer Hospital, Hexi District, Tianjin, China